Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in damages, in an ongoing ...
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE ... The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.
2d
Medpage Today on MSNNovel Drug Shrinks 73% of HER2-Mutant Lung Cancers"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results